Apoptosis signal-regulating kinase inhibitor

Patent metadata

Field	Value
Publication number	US-9333197-B2
Application number	US-201414254359-A
Country	US
Kind code	B2
Filing date	Apr 16, 2014
Priority date	Jan 27, 2012
Publication date	May 10, 2016
Grant date	May 10, 2016

Abstract

The present invention relates to a compound of formula (I):

The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.

First claim

What is claimed is:

1. A method of treating a inhibiting kidney disease fibrosis comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I)

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the kidney-disease fibrosis is associated with diabetic kidney disease.

3. The method of claim 1 , wherein the pharmaceutically acceptable salt is the hydrochloride salt.

4. The method of claim 1 , wherein the therapeutic amount ranges from 1 mg to 250 mg.

5. The method of claim 1 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered orally.

6. The method of claim 1 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a single or multiple doses.

7. The method of claim 1 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in combination with other therapeutic agents.

8. The method of claim 7 , wherein the one or more therapeutic agents is selected from the group consisting of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, antihypertensive agents, antibiotic agents, analgesic agents, antidepressant agents, or antianxiety agents.

9. The method of claim 7 , wherein the pharmaceutical composition and the one or more therapeutic agents are administered simultaneously.

10. The method of claim 7 , wherein the pharmaceutical composition and the one or more therapeutic agents are administered one after the other within intervals.

11. A method of treating fibrosis in a kidney comprising administering to a patient in need thereof a pharmaceutical composition comprising a compound of formula (I)

or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 , wherein the pharmaceutically acceptable salt is the hydrochloride salt.

13. The method of claim 11 , wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers.

14. The method of claim 11 , wherein the pharmaceutical composition is prepared for delivery as solid tablets.

15. The method of claim 11 , wherein the pharmaceutical composition is administered in a single or multiple doses.

16. The method of claim 15 , wherein the dose comprises 1 mg to 250 mg of the compound of formula (I).

17. The method of claim 11 , wherein the pharmaceutical composition is administered orally.

18. The method of claim 11 , wherein the pharmaceutical composition is administered in combination with one or more therapeutic agents.

19. The method of claim 18 , wherein the one or more therapeutic agents is selected from the group consisting of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, antihypertensive agents, antibiotic agents, analgesic agents, antidepressant agents, or antianxiety agents.

20. The method of claim 18 , wherein the pharmaceutical composition and the one or more therapeutic agents are administered simultaneously.

21. The method of claim 18 , wherein the pharmaceutical composition and the one or more therapeutic agents are administered one after the other within intervals.

Assignees

• Notte Gregory
• Gilead Sciences Inc

Inventors

• Notte Gregory

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title